A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults
Completed · Phase 1
Conditions studied: Healthy Adults
In brief
Study has two arms. Arm 1 has two cohorts in which each cohort, under the fasted state, will either be given a single oral dose of Form 1 in Period 1 followed by a single oral dose of Form 5 in Period 2 or a single oral dose of Form 5 in Period 1 followed by a single oral dose of Form 1 in Period 2. A single oral dose of Form 1 will be administered in Arm 2 Period 1 under the fasted state. The results from Arm 1 will inform whether a different dose of Form 5 will be administered under the fasted state or if Form 5 will be administered under the fed state in Arm 2 Period 2.
Key facts
- Study ID
- NCT07117799
- Run by
- Pfizer
- People needed
- 24
- Starts
- 2025-02-04
- Expected to finish
- 2025-07-11
- Last updated by the study team
- 2025-12-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Participants of nonchildbearing potential , inclusive, at screening, who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead electrocardiograms (ECGs).
- Body mass index (BMI) of 18-32 kg/m2; and a total body weight >50 kg (110 lb)
You may not qualify if…
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention
- Prior use of epigenetic modifying agents
- Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s)
- Additionally, current use or anticipated need for food or drugs that are known strong inducers or inhibitors of CYP2C9 or CYP3A4, including their administration within 14 days or 5 half-live of the strong inducers or inhibitors of CYP2C9 or CYP3A4, whichever is longer, prior to first dose of study intervention, during the treatment period, and within 2 days after the last dose of PF-07248144
- Proton pump inhibitors must be discontinued at least 5 days prior to the first dose of study medication and throughout treatment period.
Where it is running
- Pfizer Clinical Research Unit - New Haven — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.